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Abstract
Background: A community pharmacy real-time electronic recording program, ProjectSTOP, enables Australian
community pharmacists to verify pseudoephedrine requests. In Western Australia the program was available for
voluntary use from April 2007 and became mandatory November 2010. This case study explores the effectiveness
of the program by reviewing the total requests for pseudoephedrine products, and the proportion of requests
which were classified as ‘denied sales’ before and after mandatory implementation. Seasonal and annual trends
in these measures are also evaluated.
Methods: ProjectSTOP data recordings for Western Australia pharmacies between 1 December 2007 and 28
February 2014 were analysed. Data included a de-identified pharmacy number and date of each pseudoephedrine
product request. The total number of requests and sale classification (allowed, denied, safety, or not recorded) were
calculated for each month/pharmacy. The potential influence of mandatory reporting using ProjectSTOP was
investigated using a Regression Discontinuity Design. Correlations between sales from the same pharmacy were
taken into account by classifying the pharmacy number as a random effect. The main effects of year (continuous
variable), and season (categorical variable) were also included in the model.
Results: There was a small but steady decline in the total requests for pseudoephedrine per month per 100,000
population (per pharmacy) from the time of mandatory reporting. The number of denied sales showed a steady
increase up until mandatory reporting, after which it showed a significant decline over time. Total sales were
heavily influenced by season, as expected (highest in winter, least in summer). The seasonal pattern was less
pronounced for denied sales, which were highest in winter and similar across other seasons. The pattern over
time for safety sales was similar to that for denied sales, with a clear change occurring around the time of
mandatory reporting.
Conclusion: Results indicate a decrease in pseudoephedrine product requests in Western Australia community
pharmacies. Findings suggest ProjectSTOP has been successful in addressing suspicious sales and potential diversion
however ongoing data review is recommended.
Abbreviations: ACC, Australian Crime Commission; ID, Identification; OTC, Over-the-counter; WA, Western Australia
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Background
Pseudoephedrine is an effective nasal decongestant in-
cluded in many cough and cold products that are avail-
able over-the-counter (OTC) in Australian community
pharmacies [1, 2]. It is similarly available without a pre-
scription in many overseas countries [3, 4]. However,
pseudoephedrine can be diverted (utilised as a precursor
in methamphetamine production in clandestine labora-
tories) illegally into methamphetamine [5, 6], which is a
more potent form of the drug amphetamine and the
most common type of illicit amphetamine available in
Australia [7]. The diversion is an ongoing concern [8, 9]
because methamphetamine, which can be inhaled, smoked
or injected, is a highly addictive substance [10]. In 2006,
the Australian Federal Police reported an upsurge in the
diversion of pseudoephedrine products in clandestine la-
boratories [11]. The most recent Illicit Drug Data Report
showed that the number and volume of amphetamine
detections at Australian borders were the highest on
record during 2012–2013 [12] and amphetamine use is
therefore a growing problem.
Various research projects and government reports have
highlighted that the diversion of pseudoephedrine is an
alarming public health concern [13–15]. Of additional
concern is the fact that illicit methamphetamine manu-
facturing can have detrimental effects on the individ-
uals involved in the manufacturing operations as well
as innocent bystanders and individuals residing nearby
[8]. A review of the literature by White et al. highlighted
the injuries associated with the pseudoephedrine-to-
methamphetamine diversion process with some reported
injuries being severe, ranging from pulmonary effects to
chemical burns [16]. Caldicott and colleagues also re-
ported the harms associated with the chemicals used in
the diversion process which are explosive in nature and
have been implicated in fatal accidents [9]. They reported
that some accidents have resulted in environmental dam-
age that impacted on local agriculture and required costly
site clean-ups. Also, illegal diversion activity has been doc-
umented to increase hospitalisations and lead to time and
money spent in legal prosecutions of those involved in
these activities [5].
In an attempt to prevent the diversion of pseudoephed-
rine to methamphetamine various regulatory restrictions
have been introduced in Australia throughout the last
decade. These regulatory restrictions are specifically aimed
at individuals referred to as ‘pseudo-runners’ who visit
pharmacies to purchase pseudoephedrine products that
are then used to manufacture methamphetamine [17]. The
regulatory restrictions involved changes in federal as well
as jurisdictional legislation. The combination of federal and
jurisdictional regulatory restrictions was needed as reports
from law enforcement agencies in 2004 indicated that
the majority of illicit methamphetamine available at
that stage was produced from pseudoephedrine prod-
ucts obtained from community pharmacies [18]. It was
therefore necessary to implement national scheduling
changes that addressed OTC pack sizes and the need for a
pharmacist’s involvement in supplies as well as additional
consumer identification and recording requirements, im-
plemented by jurisdictions.
At federal level, the Therapeutic Goods Administration
rescheduled OTC products containing pseudoephedrine
in 2006 from Schedule 2 (Pharmacy Medicine) to Sched-
ule 3 (Pharmacist Only Medicine), thus classifying them
as non-prescription items that can only be supplied with
direct involvement of a pharmacist [19]. This change in-
cluded prohibition of advertising pseudoephedrine prod-
ucts to the general public in a further attempt to reduce
inappropriate use [1]. Additionally, all liquid preparations
that contained over 800 mg and packages of products that
contained over 720 mg of pseudoephedrine were resched-
uled to Schedule 4 (Prescription Medicine). These changes
were made to reduce pseudoephedrine availability to
the public and formalise pharmacists’ role in determin-
ing whether a consumer has a therapeutic need for a
pseudoephedrine product. Similar changes have been in-
troduced internationally [20, 21] with varied results [22].
At jurisdictional level all Australian states and terri-
tories made changes to drugs and poisons legislation to
address the management of requests, selling and re-
cording of pseudoephedrine. Changes to the Poisons
Regulations 1965 (WA) in July 2007 incorporated the
requirement to verify the purchaser’s identification and
record the sale of all pseudoephedrine products [23].
All other jurisdictions except Tasmania and Victoria
introduced similar legislation [24]. Queensland also in-
corporated an additional approach to combat inappropri-
ate sales through the introduction of a linked electronic
medication recording system called ProjectSTOP in
November 2005 [25]. ProjectSTOP is a web-based system
that allows the pharmacist to enter details of a potential
customer from approved standard identifying documents
(i.e. drivers licence). If a set system threshold to access
pseudoephedrine products is breached the system displays
previous recent sales, therefore allowing the pharmacist
to review previous sales of pseudoephedrine-containing
products, as well as instances where sales may have
been denied, for this person. As it is continually up-
dated in real time, ProjectSTOP assists pharmacists in
the decision to supply a pseudoephedrine product or
not, regardless of whether it has been prescribed or
not [26]. The system was developed by GuildLink (a
wholly owned subsidiary company of the Pharmacy
Guild of Australia) and the Chemical Diversion Desk
of the Queensland Police Service [27], with the ex-
press purpose of preventing pseudo-runners from acces-
sing pseudoephedrine.
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Each recording in the linked electronic medication
recording system includes the pharmacy identification
(ID) number, postcode, state, date of transaction, prod-
uct formulation, quantity and ingredients as well as
customer details. Customer details include date of birth,
full name, full address and photo ID type i.e. driver’s
license or proof of age card. A check of the customer ID
is then conducted through ProjectSTOP which results in
either a match or no match. A no match result indicates
that the customer’s ID has not been entered into the
system within the threshold period whereas a match
indicates a recent transaction that breached the thresh-
old period or a recent pseudoephedrine product pur-
chase. Depending on the customer’s record, the sale of a
pseudoephedrine product could then be allowed, denied
or classified as a safety sale (where the pharmacy staff
may supply the product out of safety concerns). The pro-
gram can also allocate to a category called not recorded to
be used when pharmacy staff did not record any customer
details but still supplied the product. There is evidence
that the real time recording system enables recognition of
suspicious and legitimate requests of pseudoephedrine-
containing products [28, 29], which may be used by the
police and health agencies to track non-legitimate pseudo-
runner users.
ProjectSTOP was introduced across other Australian
states during 2007 as a voluntary reporting tool. Real time
recording subsequently became mandatory in Queensland,
South Australia, Western Australia (November 2010)
and the Australian Capital and Northern Territories.
Victoria, Tasmania and New South Wales still operate
under a voluntary reporting system [24]. A recent com-
parison of pharmacy-reported pseudoephedrine sales
between Queensland and Victoria showed an increased
uptake and use of the recording system in a jurisdiction
with mandatory real-time recording requirements com-
pared to a jurisdiction with voluntary recording re-
quirements [29].
The purpose of the present study was to investigate
whether the introduction of mandatory real-time record-
ing in Western Australia (WA) influenced the number
of requests for pseudoephedrine (per 100,000 popula-
tion) from community pharmacies, or the proportion of
requests which were denied. Seasonal differences and
trends over time were taken into account.
Methods
Data entered into ProjectSTOP by WA community phar-
macies were provided by GuildLink following a confidenti-
ality agreement between Curtin University and GuildLink.
This study was conducted between July and October 2014.
Low-risk ethical approval was granted by Curtin University
(PH-14-14).
Data preparation
More than 2.5 million retrospective pharmacy records
were received from GuildLink covering WA community
pharmacy sales between 1 December 2007 and 28 Feb
2014. The population estimates for WA were obtained
from the Australian Bureau of Statistics [30]. Monthly
estimates were obtained by interpolating between census
dates.
The total number of requests for pseudoephedrine and
the proportion of those requests which were denied were
calculated for each month. The total requests per 100,000
population was calculated by reference to the monthly
population figures. The seasons (southern hemisphere)
were defined according to the month, so that December,
January, February were classified as Summer; March,
April, May as Autumn; June, July, August as Winter;
and September, October, November as Spring. Sales of
pseudoephedrine were expected to follow a seasonal
pattern with most sales occurring during winter months.
Statistical methods
Total monthly sales and denied sales per pharmacy were
calculated and summarised in graphs after adjusting for
total population figures (sales expressed as number per
100,000 population). The potential influence of mandatory
reporting using ProjectSTOP was investigated using a Re-
gression Discontinuity Design [31]. In particular, a Gener-
alised Estimating Equation was used with the monthly
number of sales at each pharmacy as dependent variable
and timing relative to the date of mandatory reporting
(pre- or post-) was included as an independent variable.
Correlations between sales from the same pharmacy were
taken into account by classifying the pharmacy number as
a random effect. This model is very similar to the Poisson
regression model, but the standard errors are corrected
for the within-pharmacy correlations. The main effects
of year (continuous variable), and season (categorical
variable) were also included in the model, which was of
the form:
Sales ¼ α þ β1  Season þ β2  Year
þ β3 Mandatory þ γ  Year Mandatory þ 
In this equation, Sales represents the number of sales
in a month at each pharmacy, Season is a categorical
variable (summer/autumn/winter/autumn), Year is the
number of months from the date of mandatory reporting
(negative if prior to the date, positive otherwise) divided
by 12, and Mandatory is a binary indicator variable which
is zero prior to reporting and ‘1’ otherwise. The coeffi-
cients (Greek letters) are estimated from the modelling
procedure, which also estimates the statistical significance
of their contributions to the model fit. In particular, β3
indicates if there is any sudden change at the date of
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mandatory reporting, and γ indicates whether the an-
nual rate of sales appears to change from pre- to post-
mandatory reporting. One model was developed with
the total number of requests for pseudoephedrine at
each pharmacy each month as dependent variable, and
a second model used as dependent variable the number
of requests which were classified as denied sales. The
intercept term in the model (α) included an offset vari-
able defined as the logarithm of the population estimate
for WA for the month, so that the rate ratios obtained
from the model were adjusted for population growth
over the period under study. Results of the regression
models were expressed as rate ratios, their 95 % confi-
dence intervals and p-values. Analyses were conducted
using the Genmod procedure in the SAS version 9.2
statistical software (SAS Institute Inc, Cary, NC, USA,
2008), and, following convention, a p-value < 0.05 was
taken to indicate a statistically significant association in
all tests.
Results
There were 2,573,905 requests for pseudoephedrine prod-
ucts recorded in the system, from 572 WA community
pharmacies between December 2007 and February 2014.
The number of pharmacies in the system correlates with
the number of community pharmacies in WA [32]. The
number of pharmacies reporting data to GuildLink grew
from 270 at the start of the period under study, in a
moderately linear fashion (Fig. 1). This suggests that
the reporting system had been gaining support steadily,
prior to it becoming mandatory. Although information
is not available on the total number of pharmacies in
WA between in 2008–2010, data from the Pharmacy
Registration Board of WA that was established in October
2010 indicates that there were 544 pharmacies in June
2011, therefore 523/544 which was a 96.1 % uptake of
ProjectSTOP. This increased to 545/563 (96.8 %) and
564/576 (97.9 %) uptake in 2012 and 2013 respectively [33].
Of all requests for pseudoephedrine, 95.7 % were
‘allowed’, 2.2 % were classified as ‘safety sale’, 1.1 % were
‘not recorded’ and 0.9 % were ‘denied’. During the same
period, the population of WA increased from 2.14 million
to 2.57 million. The crude (unadjusted) average monthly
number of requests for products changed from 3.8 per
100,000 population prior to mandatory reporting, to 3.1
per 100,000 population following its introduction.
Analysis of total requests for pseudoephedrine products
Figure 2 shows the total monthly requests for pseudo-
ephedrine per 100,000 population over the time of the
study. There is a very clear seasonal trend, which is con-
firmed in the regression analysis (Table 1). The monthly
requests were highest in winter, and lowest in summer,
with spring and autumn intermediate in number. Rates
in spring and autumn were similar, but all other pairwise
differences in rates between seasons were found to be
significantly different. After adjustment for the very sig-
nificant difference between seasons, there was no apparent
change in requests around the time of the mandatory
reporting (χ2 (1) = 0.9; p = 0.36). While there was no
Fig. 1 Number of pharmacies reporting data to GuildLink over the period under study. The vertical dashed line shows the time at which mandatory
reporting was introduced
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significant overall trend across time, there did appear to
be a significant change in slope of the line from the time
of mandatory reporting (χ2 (1) = 4.2; p = 0.0415). The an-
nual rate of change in total sales per population reduced
to 0.93 from November 2010.
Analysis of the trends in denied sales
The number of requests for pseudoephedrine per month
which were denied are shown in Fig. 3 (per 100,000
population). The vertical line shows the time at which
mandatory reporting was introduced. The regression
analysis (Table 2) shows a higher number of denied sales
in winter compared other seasons, and pairwise differ-
ences show that the rate in winter was significantly higher
than that for summer (χ2 (1) = 8.0; p = 0.0048) or spring
(χ2 (1) = 8.0; p = 0.0.0047), but not significantly different
from autumn (χ2 (1) = 1.5; p = 0.229). There was a sig-
nificant change in the slope of the line pre- to post-
mandatory reporting, with the rate changing from
significantly increasing to significantly decreasing. For some
6–8 months after introduction of mandatory reporting, the
trend in denied sales was flat, reflected in the results as a
discontinuity at the time of mandatory reporting itself.
The pattern for safety sales was similar to total and de-
nied sales (Fig. 4), and the analysis showed a clear change
in slope from pre- to post-mandatory reporting (χ2 (1) =
36.1; p < 0.0001). It also showed a significant seasonal
affect (χ2 (3) = 54.6; p < 0.0001), similar to that for total
sales (rates highest in winter, lowest in summer). There
was no discontinuity at the time of mandatory reporting
(χ2 (1) = 0.1; p = 0.77), suggesting that there was no signifi-
cant delay between the increasing trend prior to this date
and the subsequent decreasing trend.
Discussion
There appeared to be a downward trend in the total
requests for pseudoephedrine products per month, as
well as very significant seasonal differences. The denied
sales, on the other hand, showed a significant increase
Fig. 2 Total requests for pseudoephedrine per pharmacy per 100,000 population per month. The vertical dashed line shows the time at which
mandatory reporting was introduced
Table 1 Regression analysis for the total requests per pharmacy
per month
Variable Chi-square (DF) Rate ratio 95 % CI p-value
Season 4741 (3) <0.0001
Summer 0.57 0.56–0.59 <0.0001
Autumn 0.99 0.98–1.01 0.4587
Winter 1.44 1.42–1.47 <.0001
Spring 1 (reference)
Mandatory 0.85 (1) 0.98 0.94–1.02 0.3578
Year 2.1 (1) 0.97 0.94–1.01 0.1463
Mandatory Yeara 4.2 (1) 0.95 0.91–1.00 0.0415
Year (before)b 0.97 0.94–1.01 0.1463
Year (after)b 0.93 0.91–0.95 <0.0001
Correlations between observations made at the same pharmacies were taken
into account as a random effect
aInteraction term between year and Mandatory (indicating pre- or post- reporting)
bSeparate annual rates pre- and post-mandatory reporting
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up to the introduction of ProjectSTOP, followed by some
6–8 months of no change and then a significant de-
crease from that time forward. The downward trend in
denied sales started approximately six months after the
introduction of ProjectSTOP as a mandatory require-
ment. Of interest is the plateauing of the trend in denied
sales following the mandatory introduction which could
suggest that consumers who were previously able to pur-
chase pseudoephedrine-containing products started to
have requests denied by pharmacies that did not up to
that time participate in ProjectSTOP. This pattern was
similar for safety sales. The strong seasonal effect in re-
quests was expected with highest demand for products
in the winter and least in summer periods. The seasonal
trend in denied sales was much weaker, but similar to
total sales with the highest numbers occurring in winter.
A number of factors may have contributed to the de-
crease in monthly sales per 100,000 population. At a phar-
macy level these included the TGA scheduling changes
introduced in 2006 and the changes to the WA Poisons
Regulations 1965, initially in 2007 with further changes in
2010 to mandate the use of ProjectSTOP from November
2010. These changes increased pharmacists’ and poten-
tially customers’ awareness of the vigilance required in the
supply of pseudoephedrine products and the prerequisite
to confirm therapeutic need. It prompted pharmacists to
be more cautious and attentive in the decision-making
process whether to allow or deny pseudoephedrine sales.
Of specific relevance is that pseudoephedrine requests
and sales information from WA pharmacies were not
linked until July 2007 and the use of ProjectSTOP was
hence recommended on a voluntary basis to facilitate data
sharing. The mandatory requirement to use ProjectSTOP
was subsequently introduced in WA in November 2010
which further enhanced WA community pharmacists’ abil-
ity to identify suspicious requests for pseudoephedrine-
containing products. Additionally, the system also provided
better intelligence to police and health agencies regard-
ing pseudo-runners and the identification of rogue
pharmacists [26, 34].
A comparison between Queensland, with mandatory
requirements to use ProjectSTOP, and Victoria that
continues on a voluntary basis, has shown a significant
Fig. 3 Total number of denied requests for pseudoephedrine per pharmacy per 100,000 population per month. The vertical dashed line shows
the time at which mandatory reporting was introduced
Table 2 Regression analysis for the monthly number of denied
sales per pharmacy
Variable Chi-square (DF) Rate ratio 95 % CI p-value
Season 12.5 (3) 0.0059
Summer 0.99 0.93–1.05 0.6748
Autumn 1.03 0.96–1.10 0.3674
Winter 1.07 1.02–1.12 0.0047
Spring 1 (reference)
Mandatory 6.5 (1) 1.17 1.04–1.31 0.0107
Year 14.9 (1) 1.14 1.09–1.20 <0.0001
Mandatory Yeara 74.3 (1) 0.70 0.64–0.76 <0.0001
Year (before)b 1.14 1.09–1.20 <0.0001
Year (after)b 0.80 0.76–0.83 <0.0001
aInteraction term between year and Mandatory (indicating pre- or post- reporting)
bSeparate annual rates pre- and post-mandatory reporting
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difference in the rate of uptake of the system [29]. The
mandatory use of ProjectSTOP should therefore ideally
be implemented in all jurisdictions to enable tracking
of pseudo-runners that visit pharmacies in different
states and territories. The Pharmacy Board of Australia
indeed endorsed the use of a real-time online monitoring
system, such as ProjectSTOP, in the Board’s Guidelines on
practice-specific issues [35].
Data show that the illegal use of methamphetamine re-
mains an ongoing concern. The 2007 National Drug Strat-
egy Household Survey reported that 6.3 % of Australians
aged 14 years and older had used meth/amphetamine,
which was relatively high compared to other illicit drugs
[36]. The Survey also showed that 2.3 % had used it for
non-medical purposes in the previous 12 months. Data
from the 2010 National Drug Strategy Household Survey
showed a slight decrease in meth/amphetamine use with
2.1 % of Australians aged 14 years and older having used
it for non-medical purposes in the previous 12 months
[37]. Of specific relevance is that a later report, the 2013
National Drug Strategy Household Survey, showed that
about 1.3 million Australians aged 14 years and older
(7 %) had used meth/amphetamines in their lifetime and
400,000 (2.1 %) had done so in the last 12 months. This
report also showed a rise in the proportion of people using
it daily or weekly [38] and hence it is an ongoing problem.
Although the overall use of illicit methamphetamines
remained relatively stable there have been statistically
significant changes in the type, namely crystal or ice
versus powder, and frequency of use [38]. The increased
use of crystal methamphetamine is concerning as it is
not only more potent and hence can cause more fatal-
ities, it also has increased potential for dependence and
chronic physical and mental problems [39]. It seems that
there have been an increase in illegal methamphetamine
imports since 2010, as reported by the Australian Crime
Commission (ACC) [40]. The ACC also reported that
this growth has occurred without a concurrent fall in
domestic production and clandestine laboratory detec-
tions and has been able to identify specific individuals
involved in pseudoephedrine sales [40]. However the
sales through WA community pharmacies have shown a
steady decline. The downward trend in pseudoephedrine
sales through WA community pharmacies therefore con-
tributes to the multi-strategy approach to reduce inappro-
priate supplies through community pharmacies.
An increased awareness of ProjectSTOP in the commu-
nity may have alerted illicit users to the possibility of being
tracked and apprehended by the authorities. This could
have dampened intentions of purchasing pseudoephedrine-
containing products from community pharmacies, and
hence the decrease in the number of denied sales. There is
also a possibility that there was a heavier reliance on other
cough and cold products such as phenylephrine-based
products to treat symptoms. Phenylephrine replaced pseu-
doephedrine in various products as a means of controlling
illicit methamphetamine activity although it has been doc-
umented that this may not solve the problem associated
with methamphetamine abuse [41] and ongoing vigilance
is required. It is also worth mentioning that studies have
Fig. 4 Total number of safety sales of pseudoephedrine per pharmacy per 100,000 population per month. The vertical dashed line shows the time
at which mandatory reporting was introduced
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shown phenylephrine to be less effective than pseudo-
ephedrine as a nasal decongestant and that the barriers
imposed on obtaining pseudoephedrine may impact on
the quality of life of consumers who have a legitimate need
for pseudoephedrine [41, 42]. This adds to the complexity
of the regulation of pseudoephedrine sales through com-
munity pharmacies.
This evaluation of pseudoephedrine recordings pro-
vides insight into the value of the real-time recording
software as a means of controlling sales of pseudoephed-
rine through community pharmacies. The findings from
this study may be of interest to legislative authorities
and policy makers in terms of the ongoing battle against
the illicit manufacture of methamphetamine from pseu-
doephedrine. The combination of regulatory restrictions
at federal and jurisdictional levels could also be useful in
the development of controls for other medicines with
potential for abuse, such as codeine containing OTC
and prescription products.
The study was limited by the scheduling changes that
occurred during the time period analysed. These sched-
uling changes could have influenced pseudoephedrine
demand patterns. Another major limitation is that the
recording of the sale type is based on the decision of the
pharmacist or pharmacist assistant. This decision could
be influenced by environmental factors, time constraints,
level of experience and personal judgement.
Conclusion
This study has provided insight into annual requests
for pseudoephedrine sales and denied and safety sale
trends before and after the mandatory implementation
of ProjectSTOP in WA. Seasonal trends show that a
higher percentage of sales are denied in the summer,
therefore pharmacists are denying sales when there do not
seem to be a therapeutic need. The use of ProjectSTOP
has been a positive step in identifying suspicious sales
from community pharmacies and subsequently combat-
ting the diversion of pseudoephedrine to methampheta-
mine. However, future studies are required to better assess
the impact of the program in reducing illicit activity.
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